

1 **Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-**
2 **expressed full-length SARS-CoV-2 S1 proteins**

3 Rongqing Zhao^{a,1}, Maohua Li^{b,1}, Hao Song^{c,1}, Jianxin Chen^d, Wenlin Ren^b,
4 Yingmei Feng^e, Jinwen Song^f, Ya Peng^c, Bin Su^e, Xianghua Guo^e, Yanjun
5 Wang^k, Jingong Chen^d, Jianli Li^b, Hunter Sun^a, Zhonghu Bai^g, WenJing
6 Cao^h, Jin Zhuⁱ, Qinlu Zhang^j, Yufei Sun^a, Sean Sun^a, Xinkun Mao^a, Junchi
7 Su^a, Hui Chen^g, Ailiang He^d, Ronghua Jin^{e*}, Le Sun^{a,b*}.

8 ^a*AnyGo Technology Co., Ltd, D1117 New China International Square, 89*

9 *Dayangfang Rd, Beijing, China;* ^b*AbMax Biotechnology Co., LTD, 99 Kechuang 14th*
10 *St., BDA, Beijing, China;* ^c*Research Network of Immunity and Health (RNIH), Beijing*
11 *Institutes of Life Science, Chinese Academy of Sciences, Beijing, China;* ^d*Zhenge*
12 *Biotechnology Co., LTD, Shanghai, China;* ^e*Beijing You an Hospital, Capital Medical*
13 *University, Beijing, China;* ^f*Treatment & Research Center for Infectious Diseases, The*
14 *Fifth Medical Center of PLA General Hospital, National Clinical Research Center for*
15 *Infectious Diseases, Beijing, China;* ^g*School of Biotechnology, Jiangnan Univ., 1800*
16 *Lihu Ave., Wuxi, Jiangsu, China;* ^h*Bengbu Medical University, Bengbu, Anhui,*
17 *China;* ⁱ*Dept. Laboratory, Quzhou People's Hospital, Quzhou, Zhejiang, China;*
18 ^j*ShaanXi Provincial Engineering Research Center for Nano-BioMedical Detection, 3-*
19 *10402A, 2 Zhang Ba Wu Rd., Xi'an, Shaanxi, China;* ^k*Beijing Institute of Hepatology,*
20 *Beijing, China.*

21 1.RQ.Z., MH.L. and H.S. contributed equally to the study as the co-first authors.

22 *Co-corresponding Authors:

23 Le Sun, Ph.D. Email: sunL@antibodychina.com. AnyGo Technology Co., Ltd, D1117
24 New China International Square, 89 Dayangfang Rd, Beijing 100122, China.

25 Ronghua Jin, Ph.D. Email: 93353503@qq.com. Beijing You an Hospital, Capital
26 Medical University, Beijing 100069, China

27

28 **Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-** 29 **expressed full-length SARS-CoV-2 S1 proteins**

30 WHO has declared COVID-19 a pandemic with more than 300,000 confirmed
31 cases and more than 14,000 deaths. There is urgent need for accurate and rapid
32 diagnostic kits. Here we report the development and validation of a COVID-
33 19/SARS-CoV-2 S1 serology ELISA kit for the detection of total anti-virus
34 antibody (IgG+IgM) titers in sera from either the general population or patients
35 suspected to be infected. For indirect ELISA, CHO-expressed recombinant full
36 length SARS-CoV-2-S1 protein with 6*His tag was used as the coating antigen to
37 capture the SARS-CoV-2-S1 antibodies specifically. The specificity of the
38 ELISA kit was determined to be 97.5%, as examined against total 412 normal
39 human sera including 257 samples collected prior to the outbreak and 155
40 collected during the outbreak. The sensitivity of the ELISA kit was determined to
41 be 97.5% by testing against 69 samples from hospitalized and/or recovered
42 COVID-19 patients. The overall accuracy rate reached 97.3%. Most importantly,
43 in one case study, the ELISA test kit was able to identify an infected person who
44 had previously been quarantined for 14 days after coming into contact with a
45 confirmed COVID-19 patient, and discharged after testing negative twice by
46 nucleic acid test. With the assays developed here, we can screen millions of
47 medical staffs in the hospitals and people in residential complex, schools, public
48 transportations, and business parks in the epidemic centers of the outbreaks to
49 fish out the “innocent viral spreaders”, and help to stop the further spreading of
50 the virus.

51 Keywords: SARS-CoV-2, COVID-19, Serological assay for SARS-CoV2
52 antibodies.

53 **Introduction**

54 As of March 24, there were 370,416 confirmed cases of COVID-19 with 16,324 deaths
55 in the world¹. Infections among healthcare providers were even more alarming, with
56 4826 Italian doctors and nurses reported to be infected over such a short period due to
57 the lack of appropriate medical protection gear and quick screening of SARS-CoV-2
58 infections^{2,3}. Making the issue even worse, the virus can be widely transmitted by

59 asymptomatic viral-carriers to people in close contact⁴, with some patients reportedly
60 becoming sick once again after their initial recovery and yielding a positive NAT test⁵.

61 There is an urgent need to develop rapid, fast and simple screening tools to find
62 “moving viral carriers” and quarantine them.

63 Nucleic acid tests (NAT), the most widely used diagnostic assay for COVID-19
64 in the world, only have a 40% accuracy rate, leading to many patients who test negative
65 on NAT to nonetheless go on to suffer severe complications, including possible
66 mortality, due to undetected SARS-CoV-2 infections^{6,7}.

67 SARS-CoV-2 is one of the seven human coronaviruses known to infect human.
68 Out of the seven members, SARS, MERS and SARS-CoV-2 have mortality rates
69 between 9-14%, while the other four members, HCoV-OC43, HCoV-NL63, HCoV-
70 229E and HCoV-HKU1, only cause mild flu syndrome and have been around for many
71 years. SARS-CoV-2 contains nucleoprotein (N-protein), spike glycoprotein (S-protein),
72 envelope protein (E-protein) and membrane protein (M-protein)^{8,9}. SARS-CoV-2’s N
73 protein shared over 90% homology with other members of the coronavirus family.
74 Cross-reactivity among N proteins of human coronaviruses was reported by Yu’s
75 group¹⁰. The S-protein can be divided into two parts: S1 and S2 proteins. The S1 protein
76 attaches the virion to the cell membrane by interacting with a host receptor (human
77 ACE2), initiating the infection¹¹. SARS-CoV-2’s S1 protein has 685 amino acids with
78 seven potential glycosylation sites¹². No evidence of strong cross-reactivity was
79 observed with many neutralizing SARS or MERS monoclonal antibodies (personal
80 communications), suggesting it has very unique antigenicity.

81 Several diagnostic kits for measuring SARS-CoV-2 IgM and IgG have been
82 approved by Chinese FDA with the restriction that they may only be used as companion
83 tests for NAT, and not to be used for general screening of SARS-CoV2 infection due to

84 lacking the required specificity and sensitivity. Possible cause may be the poor quality
85 of the detecting antigens used. Three different types of antigens were reported to be
86 used: 1) the recombinant N protein from SARS-CoV-2, which is highly conserved
87 among all 7 members of coronaviruses and led to poor specificity in tests of general
88 population, 2) CHO-expressed S1 protein from SARS-CoV-2, which has very different
89 antigenicity from its counterpart in SARS-CoV-2, or 3) the receptor binding domain
90 (RBD) of SARS-CoV-2 S1, which is about 200 amino acids long with only one
91 glycosylation, compared to the full length S1 which has 7 glycosylation sites. These
92 latter two can result in poor sensitivities. Misdiagnose of HCoV-OC43, HCoV-NL63,
93 HCoV-229E and HCoV-HKU1 infections as SARS-CoV-2 could send thousands and
94 thousands of people to already over-loaded hospitals and increase the risk of real
95 infection by SARS-CoV-2 during the unnecessary hospital visit. On the other hand,
96 missed detections of SARS-CoV-2 infections can deny patients the opportunity to
97 receive early preventative care before the disease progresses into acute respiratory
98 syndrome, which has an over 60% mortality rate. Therefore, it is extremely important to
99 develop serological tests using the right detecting antigen: fully glycosylated, full length
100 SARS-CoV-2 S1 recombinant protein(s).

101 The full length SARS-CoV-2 S1 protein has previously been difficult to express
102 at a commercially viable level (personal communications), but using our patented
103 technology, we have improved the expression level by close to a hundred fold
104 (~80mg/L) using either CHO or 293F mammalian cells. Using the CHO-expressed
105 SARS-CoV-2 S1 protein as the detecting antigens, we have developed a very sensitive
106 and highly specific diagnostic assay for screening the health care staff at the hospitals to
107 reduce the in-hospital infections, and checking the in-coming visitors from the epidemic

108 areas, and the work forces coming back to work, and the general populations for SARS-
109 CoV-2 viral infection.

110 **Materials and methods**

111 *Reagents and supplies*

112 Freund's complete adjuvant (CFA), Freund's incomplete adjuvant (IFA), Polyethylene
113 glycol 4000 (PEG4000), DMSO, TMB substrates were purchased from SIGMA, USA.
114 High-binding 96-well ELISA plates were purchased from Corning, USA. L-glutamine,
115 antibiotics. ELISA buffers and solutions were prepared using analytic reagent-grade
116 chemicals unless specified otherwise. Goat anti-human IgG (H+L) peroxidase conjugate
117 was sourced from Jackson Immunoresearch, USA. Cynomolgus monkeys were hosted
118 at Xierxing Biotech., Beijing, China. Mouse anti-His 6X mAb 6E2 was provided by
119 AbMax. HEK 293F cells and CHO cells and culture media were provided by Zhenge
120 Biotech., Shanghai, China. SDS-PAGE precast gels were purchased from GenScript,
121 China.

122 *Protein expression and purification*

123 The full length SRARS-CoV-2 S1 gene (GenBank: QIC53204.1) with C terminal were
124 synthesized by GENEWIZ, China, and inserted into mammalian cell expression vectors
125 with either 6*His tag or fused with human IgG Fc. The purified plasmid DNA was used
126 to transfect mammalian CHO and human 293F cells by lipofection using liposome
127 transfection kit (Invitrogen, USA) following manufacturer's instructions. The
128 transfected mammalian cells were grown at 37°C and 5% CO₂ for a few days prior to
129 harvesting. The harvested cells were pelleted by centrifugation at 4,000 rpm for 10
130 minutes. The recombinant S1-His6X protein was by immobilized metal affinity

131 chromatography. The recombinant S1-Fc protein was purified by Protein A
132 chromatography. Protein concentration was determined by OD absorbance at 280nm.
133 The purity and identity of the purified recombinant SRAR-CoV-2 S1 proteins were
134 ascertained by SDS-PAGE, Coomassie brilliant blue staining and ELISA with anti-
135 6*His mAb. Briefly, the samples were loaded onto 12% gels, separated by SDS-PAGE,
136 either stained with Coomassie brilliant blue staining for purity.

137 ***Generation of monkey polyclonal antibodies***

138 10 months-old Cynomolgus monkeys were first immunized with CHO-expressed S1-Fc
139 fusion protein in Complete Freund's Adjuvant and boosted in Incomplete Freund's
140 Adjuvant. Two to four weeks after the first immunization, bleeds were tested for titers
141 by indirect Enzyme-linked Immunoassay (ELISA).

142 ***Serum samples for assay***

143 The protocols were approved by the institutional ethical committee of Beijing You An
144 Hospital, Capital Medical University. Strong negative plasma samples and negative
145 ones were obtained from human subjects that were collected prior to and during the
146 COVID-19 outbreak respectively. Plasma samples were also obtained from hospitalized
147 and/or recovered patients confirmed SARS-CoV-2 virus infection. Informed consent
148 was obtained from all the human subjects who participated in the study after the nature
149 and possible consequences of this study had been fully explained and the protocols were
150 approved by the institutional ethical committee. The serum samples were inactivated at
151 56 °C for 30 min and stored at -20 °C until used.

152 ***SARS-CoV-2 virus serology ELISA kit***

153 Briefly, known amount of recombinant full length SARS-CoV-2 S1-His was diluted in

154 PBS (10 mM, pH 7.4) and 100 μ L of the solution was added to each well of 96-well
155 high binding ELISA plates (8 wells/strip, Corning, USA) and incubated overnight at 2-
156 8°C. The wells were emptied and washed twice with PBS and unsaturated sites were
157 blocked with 3% BSA in PBS by incubating for 1 hour at room temperature. Coated
158 plates were air-dried and sealed in plastic bags and stored at 2-8°C until used.

159 Anti-SARS-CoV-2 S1-Fc monkey pAbs or human plasma sample were first
160 diluted in negative human sera (pooled serum from 8 human subjects prior to the
161 outbreak of COVID-19). For ELISA, each serum sample was tested in duplicates and 46
162 samples can be accommodated on one plate. Prior to test, human samples or the
163 standards were diluted 1:20 in sample dilution buffer, such as 20% Calf-serum (CS) in
164 PBS. 100 μ L of appropriately diluted sample was added to each well of the S1-His-
165 coated plates and incubated for 1 hour at 37°C with constant shaking. The wells were
166 emptied and washed twice with PBS containing 0.1% Tween 20 (PBST). 100 μ L of
167 appropriately diluted goat anti-human IgG (H+L) peroxidase conjugate in 20%CS in
168 PBS was added to the respective wells and incubated for another 1 hour at 37°C with
169 constant shaking. The wells were emptied and washed five times with PBST before
170 addition of TMB substrate solutions. The chromogenic development was stopped using
171 0.1M H₂SO₄ after 15 minutes of incubation in the dark. Optical density (OD) was
172 measured at 450nm wave length in a microplate spectrophotometer (Thermo Scientific,
173 Multiskan MK3).

174 Calculate the mean value (AVG1) of Negative control, and times the lot-specific
175 converting factor (CF) as the negative cut-off point (N-Cut); calculate the mean value
176 (AVG2) of Weak positive control, use AVG2 as the positive cut-off point (P-Cut). If the
177 absorbance value of the sample is greater than or equal to the positive cut-off point (P-
178 Cut), the result of the sample is positive, indicating that the sample has detected

179 antibodies that recognize the SARS-CoV-2; if the absorbance value of the sample is less
180 than the negative cut-off point (N-Cut), the result of the sample is negative, it means
181 that no antibody that recognizes the SARS-CoV-2 is detected in the sample; if the
182 absorbance value of the sample is less than the positive critical point value (P-Cut) and
183 greater than or equal to the negative critical point value (N-Cut), the result of the sample
184 falls into a grey area and needs further experimental confirmation.

185 **Results**

186 *Construction, expression and purification of recombinant SARS-CoV2 S1* 187 *proteins*

188 The Spike protein S1 plays a key role in virus binding and entering host cells via human
189 ACE2. It has 685 amino acids with 7 potential glycosylation sites, and its heavy
190 glycosylation made it with very distinguishable antigenicity from its close family
191 members SARS and MERS, demonstrated by the no significant cross reactivity was
192 observed with existing neutralizing mAbs to SARS or MERS. The DNA sequence
193 corresponding to the full length SARS-CoV-2 S1 protein was chemically synthesized
194 and inserted into two different mammalian cell expression vectors with either 6XHis tag
195 or human IgG Fc region to produce two versions of recombinant SARS-CoV-2 proteins,
196 S1-His and S1-Fc (Fig. 1A).

197 Culture supernatants were purified using either Ni column or Protein A column.
198 As shown in Fig.1B, a defused band was observed around 120 kD in elution (Lane 5
199 and 6), which is much larger than the expected size of S1-His, suggesting heavy
200 glycosylation took place. Two sharp bands at 500 kD or higher were detected in the
201 elution of Protein A column (Fig. 1C), representing dimer and oligomer of S1-Fc.

202 Multiple batches of expressions and purifications of both S1-His and S1-Fc
203 recombinant proteins using two mammalian cell systems have been carried out. The
204 culture supernatants and cell lysates were collected at different times and the expression
205 levels were examined by ELISA using mouse anti 6*His tag mAb 6E2. Using our
206 patented technology, the transient expression levels of S1-His and S1-Fc in either CHO
207 cells or 293F cells reached 30-72mg/L (Table S1). Stable cell lines just established
208 recently.

209 ***Characterization of the purified recombinant SARS-CoV-2 S1 proteins***

210 To verify the true identity, the purified recombinant S1-His protein was coated on to 96-
211 well plate and examined with the plasma samples collected from recovered COVID-19
212 patients. As shown in Fig. 2A, all six plasma samples reacted strongly with the purified
213 recombinant SARS-CoV-2 S1 protein, indicating not only the right sequence but also
214 the correct conformation.

215 To generate the positive controls for the COVID-19 serological assays, two
216 monkeys were immunized with recombinant S1-Fc with the help of adjuvant. As shown
217 in Fig. 2B, on day 16, both monkeys developed very strong immune reactivity against
218 S1-His, with titers at 1:200 for the male monkey and 1:800 for the female one. The two
219 sera were mixed and used to spike the human normal sera for preparation of the positive
220 controls.

221 ***Development of Serological assays for SARS-CoV-2 antibodies.***

222 To evaluate the effect of S1-His protein coating concentrations for capturing anti-
223 SARS-CoV-2 antibodies in testing samples, each well of 96-well EIA plate was coated
224 with 100 μ L of S1-His protein at eight different concentrations (0.1, 0.2, 0.4, 0.5, 0.8,
225 1.0, 1.2 and 1.5 μ g/mL) in 10mM PBS pH 7.4 at 2-8°C overnight.

226 The solid phase-bound S1-His protein was probed using appropriately diluted
227 mouse anti-S1-His mAb 6E2 (0, 2, 5, 20 $\mu\text{g/mL}$). As shown in Table S2, at all eight
228 different coating concentrations of S1-His, the OD values showed dose dependency,
229 while the maximal OD values increased with increasing coating concentrations of S1-
230 His protein. Since the background OD values did not change significantly, 1.5 $\mu\text{g/mL}$
231 concentration of S1-His protein was considered optimal for coating of ELISA plate for
232 kit manufacture to ensure the highest sensitivity.

233 There is a need to dilute testing human sera since matrix components, especially
234 the host antibodies, can contribute to high assay background if undiluted. A set of 8
235 strong negative plasma samples (collected prior to the outbreak of COVID-19) were
236 tested at five different dilutions to experimentally determine the assay's optimal
237 dilution.

238 As shown in Table S3, if the dilution is not high enough, such as 1:5 or 1:10, the
239 background is too high. At 1:20 or higher dilutions, the background was acceptable.
240 Base on suggestions from the clinicians, 1:20 dilution is more practical and determined
241 to be the dilution rate for future use.

242 To balance between preservation of the detection of weak affinity SARS-CoV-2
243 antibodies and reduction of background, we have tried different washing, sample
244 dilution and enzyme dilution buffers.

245 Addition of detergent for sure will reduce the non-specific binding of antibodies
246 binding to the plates, but too much of it will also remove some of the blocking of the
247 plate and give more opportunity for non-specific binding. As you can see from Fig. 3A,
248 with detergent Tween-20 in the washing buffers, the background was significantly
249 reduced.

250 We also examined the influences of the sample dilution buffers, enzyme dilution
251 buffers and assay conditions on the performance of the tests. Human plasma or serum
252 contains extremely high level of antibodies which will non-specifically bind to the wells
253 and could potentially increase the background significantly. One approach is to use non-
254 human sera, such as calf-serum (CS), to compete for the non-specific binding. In this
255 study, we tested both 3% BSA-PBS and 20% CS-PBS as the sample dilution buffers
256 against 8 normal human plasma samples, the human negative control, the strong human
257 negative control and human sera spiked with various amounts of sera from SARS-CoV-
258 2 S1-Fc immunized monkeys. In the same experiment, we also tried the incubation with
259 or without the constant shaking. As shown in Fig. 3B & 3C, 20%CS-PBS significantly
260 reduced the background, comparing to 3% BSA-PBS, with much better signal-to-noise
261 (S/N) ratio. Although taping the plates every 10 minutes produced similar results as
262 constant shaking, it is still highly recommended to use temperature controlled
263 microplate shaker.

264 Based on above data, the best manufacturing and key testing parameters for the
265 SARS-CoV-2 serological ELISA kit were selected as 1) 1.5 μ g/mL SARS-CoV2 S1-His
266 for plate coating, 2) 1:20 dilution of human sera using 20% CS-PBS as sample and
267 enzyme diluent, 3) incubation with constant rotation using a temperature controlled
268 micro-plate shaker.

269 ***Reproducibility: Intra-assay and inter-assay precisions***

270 Several batches of the SARS-CoV2 serology ELISA kits were manufactured at three
271 different locations, and were tested using positive monkey sera at different dilutions in
272 human sera for assessing the reproducibility of manufacturing and assay precisions.

273 Summarized in Table S4, all three batch's Intra-CVs were in the range of 6.39-
274 12.05%, which is within the acceptable criterion of less than or equal to 15%. The intra-
275 assay imprecision of samples (CV) was around 10.38%.

276 ***Specificity of the serological ELISA assay***

277 The diagnostic specificity of the kit was demonstrated by testing 412 human samples
278 including 257 samples collected prior to (strong negatives) and 155 samples collected
279 during (negatives) the outbreak of COVID-19.

280 As shown in Table 1, for the strong negatives, obtained from different sources
281 including 48 samples from Rabies vaccinated patients, showed very similar specificities
282 between 95.6-100%. In the group of Commercial #2, they were from 50 Blacks, 30
283 Whites, 24 Asian females and 20 Asian males, and no significant difference in
284 background was observed between different races or genders. The specificity for strong
285 negative was determined at 96.9%.

286 For the negatives, group #1 was collected from Beijing, and groups #2-4 were
287 collected from Zhejiang province, both areas have confirmed COVID-19 cases. In the
288 initial test, 2 of the 15 samples from Beijing's group were tested antibody-positive
289 (Table 1). We performed the antigen competition assay using the rec. S1-His proteins at
290 very high concentrations, and found that the signals could not be blocked, suggesting
291 those two were false negatives. No positive was detected in the other three groups. The
292 specificity was 98.7%. Combine the data from the strong negative samples, the overall
293 specificity of the ELISA kit was 97.5% (402/412).

294 ***Sensitivity of the serological ELISA assay***

295 In collaboration with Chinese CDC, the ELISA kits were sent to several hospitals
296 including two in Beijing and one in Wuhan to examine its sensitivity against the real

297 clinic samples. Some of the data were presented in Fig. 4A-D. One study group
298 encompass of 45 clinic samples from COVID-19 confirmed patients at different clinic
299 stages at different ages with different genders. As shown in Fig. 4A, out of the 45
300 samples, 44 tested positive for SARS-CoV2 antibodies with a sensitivity of 97.7%.
301 There were 21 samples (one on day-1, 3 on day-3, 7 each on days-4 and -5, 2 on day-6
302 and 1 on day-7) collected within one week of onset of COVID-19 diseases, all of them
303 tested positive for SARS-CoV-2. So far, no significant difference in antibody levels
304 observed between different genders or ages (Fig. 4B & 4C).

305 In another group of study, shown in Fig. 4D, 23 out of 24 clinic samples were
306 tested positive for SARS-CoV-2 antibodies. We sort the samples by collecting time 1)
307 one day after hospitalization (Hosp-Day 1), 2) anytime during the hospitalization
308 (Hospitalized), 3) follow-up on day 14 post-release from the hospital (Follow-14).
309 Clearly, the ones just arrived at the hospital had the lowest levels of SARS-CoV-2
310 antibodies. The antibody levels increased during the treatments and after been released
311 from the hospitals. More works will be carried out to exam the levels of IgG and IgM of
312 those positive samples respectively by simply changing the goat-anti-human IgG (H+L)
313 secondary antibodies, which will detect both IgG and IgM, to goat-anti-human IgG Fc
314 specific secondary antibodies and mouse anti-human μ Chain-specific mAb.

315 As summarized in Table 2, the overall sensitivity of the serological assay for
316 SARS-CoV2 total antibodies was 97.1%.

317 Using the assay as screening tool for epidemiology study, in one case, there
318 were five persons who were in close contact of confirmed COVID-19 patients and they
319 had been quarantine for 14 days, showed no sign of sickness, tested negative twice by
320 NAT and were released. One of them was tested positive for SARS-CoV-2 by this
321 serological ELISA kit. This ELISA assay may offer a tool for the CDC teams who

322 stayed in WuHan to search the clues for those new COVID-19 cases surfaced recently
323 who had no clear connection with any confirmed COVID-19 patients.

324 **Discussion**

325 The S1 protein binds to ACE2 protein on the surface of the human cells and plays
326 critical role in virus infection. Our data showed that the S1 protein of SARS-CoV-2
327 virus is heavily glycosylated, evidenced by the purified S1-His protein which had an
328 apparent molecular weight of 120 kD on SDS-PAGE gel, while its calculated molecular
329 weight should be just around 70 kD. Glycosylation not only help the protein folding
330 correctly, but also contribute greatly to protein's affinity to its receptor. For example,
331 the binding affinity of IgG1 to FcγRs on effector cell surfaces is highly dependent on
332 the N-linked glycan at asparagine 297 (N297) in its CH2 domain^{14,15}, with a loss of
333 binding to the FcγRs observed in N297A point mutants^{16,17}. Even the nature of the
334 carbohydrate attached to N297 modulates the affinity of the FcγR interaction as
335 well^{18,19}.

336 In this study, full-length SARS-CoV-2 S1 proteins were expressed using both
337 human 293F cells and Chinese hamster ovarian cells to ensure the recombinant proteins
338 have the correct glycosylation profiles to resemble the native conformation on the
339 surface of virus. Using our patented technology, we have successfully increased the
340 expression levels of the full length recombinant SARS-CoV-2 S1 proteins up to
341 70mg/L. Using the CHO cell expressed full length SARS-CoV-2 S1-His protein as the
342 capturing antigen, we have been able to develop a COVID-19 serological ELISA kit
343 with high specificity (97.5%) and great sensitivity (97.1%). With an accuracy of 97.3%,
344 the assay we developed here will be well suited for screening the health care staff to
345 reduce in-hospital transfection of SARS-CoV-2 virus. Rapid Immunochromatographic
346 Assay (RICA) was also developed using a double antigens Sandwich format. It is now

347 in clinic study for its specificity and sensitivity. Once finished, we will have another
348 tool to help patients to test at home so they either can receive early preventative care
349 before the disease progresses into acute respiratory syndrome or not making un-
350 necessary hospital visits for regular flu.

351 **Author contributions**

352 RQZ, MHL, WLR, JXC, JGC, JLL, ALH contributed the development of recombinant
353 proteins and assay development. WLR, YFS, ZHB, ZYS, QLZ, XKM, JCS, HC
354 contributed in the pilot productions of assay kits. HS, YMF, XHG, JWS, YP, BS, YJW,
355 WJC, JZ contributed the clinic studies. HS, SS contributed in market studies and
356 technical writing.

357 **Acknowledgements**

358 This work is supported by Research Grants from Beijing Science and Technology
359 Commission, and Bill & Melinda Gates Foundation to Le Sun. This work was also
360 supported by the National Natural Science Foundation of China (NSFC) (81702015),
361 and the National Science and Technology Major Project (2018ZX10733403) to H.S. We
362 thank Professor Wenjie Tan from National Institute for Viral Disease Control and
363 Prevention, Chinese Center for Disease Control and Prevention for providing the
364 sequences of SARS-CoV-2 S1 protien.

365 **References**

- 366 1. “Reports of COVID-19 Pandemics, Confirmed cases and deaths in and outside of China.”
367 www.163.com Mar. 24, 2020.
- 368 2. “Surging health care worker quarantines raise concerns as coronavirus spreads”
369 www.khn.org Mar. 10, 2020.
- 370 3. “Thousands of medical staff infected by coronavirus in Italy” Gruppo Italiano per la
371 Medicina Basata sulle Evidenze, Mar. 18, 2020.

- 372 4. “New cases of COVID-19 patients with no direct connections to confirmed patients
373 surfaced at the clinics in Wuhan, a danger sign!” Health Daily, Mar. 17, 2020.
- 374 5. “Three members from the same family sick and NAT positive again. Expert cautioned
375 maybe “false-cure”. Health Daily Mar. 21, 2020.
- 376 6. “Field Experts answered NAT will not be the only diagnose evidence” People’s Daily, Feb.
377 9, 2020.
- 378 7. “17 year-old Korean boy died of COVID-19 but tested negative in 14 NAT” Korea Central
379 Daily, Mar. 19, 2020.
- 380 8. Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and
381 pathogenesis. *Nature reviews. Microbiology* 7, 439-450, doi:10.1038/nrmicro2147 (2009).
- 382 9. Stadler, K. et al. SARS--beginning to understand a new virus. *Nature reviews.*
383 *Microbiology* 1, 209-218 (2003).
- 384 10. Yu, F., Le, M. Q., Inoue, S., Thai, H. T. C., Hasebe, F., Del Carmen, P. M. et al. (2005).
385 Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus
386 infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein-
387 based enzyme-linked immunosorbent assay. *Clin. Diagn.Lab.Immunol.* 12, 848–854.
- 388 11. Stertz, S. et al. The intracellular sites of early replication and budding of SARS-
389 coronavirus. *Virology* 361, 304-315, (2007).
- 390 12. Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of
391 the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *The*
392 *Journal of biological chemistry* 279, 3197-3201 (2004).
- 393 13. Wu,F., Zhao,S., Yu,B., Chen,Y.-M., Wang,W., Hu,Y., Song,Z.-G., Tao,Z.-W., Tian,J.-H.,
394 Pei,Y.-Y., Yuan,M.L., Zhang,Y.-L., Dai,F.-H., Liu,Y., Wang,Q.-M., Zheng,J.-J., Xu,L.,
395 Holmes,E.C. and Zhang,Y.-Z. A novel coronavirus associated with a respiratory disease in
396 Wuhan of Hubei province, China. Unpublished. *ACCESSION YP_009724390*
- 397 14. Jefferis, R. & Lund, J. Interaction sites on human IgG-Fc for FcγR: current models.
398 *Immunology letters* 82, 57-65 (2002).
- 399 15. Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M. & Dwek, R.A. The impact of
400 glycosylation on the biological function and structure of human immunoglobulins. *Annual*
401 *review of immunology* 25, 21-50 (2007).
- 402 16. Shields, R.L. et al. High resolution mapping of the binding site on human IgG1 for Fc
403 γR1, Fc γR2, Fc γR3, and FcγRn and design of IgG1 variants with
404 improved binding to the Fc γR. *The Journal of biological chemistry* 276, 6591-6604
405 (2001).
- 406 17. Tao, M.H. & Morrison, S.L. Studies of a glycosylated chimeric mouse-human IgG. Role of
407 carbohydrate in the structure and effector functions mediated by the human IgG constant
408 region. *Journal of immunology* 143, 2595-2601 (1989).

- 409 18. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of
410 immunoglobulin G resulting from Fc sialylation. *Science* 313, 670-673 (2006).
- 411 19. Shields, R.L. et al. Lack of focus on human IgG1 N-linked oligosaccharide improves
412 binding to human Fc gamma RIII and antibody-dependent cellular toxicity. *The Journal of*
413 *biological chemistry* 277, 26733-26740 (2002).

414 **Table 1 Specificity and sensitivity assay against strong negative samples**

Groups	Sources	SARS-CoV-2 Ab	SARS-CoV-2 Ab	Sub	Specificity
		Negative	Positive	Total	
Strong Negative	Rabies vaccinated	47	1	48	97.9%
	Commercial #1	20	0	20	100.0%
	Commercial #2	119	5	124	96.0%
	Hospital #3	43	2	45	95.6%
	Clinical Lab	20	0	20	100.0%
Total		249	8	257	96.9%
Negative	Group #1	13	2	15	86.7%
	Group #2	9	0	9	100.0%
	Group #3	123	0	123	100.0%
	Group #4	8	0	8	100.0%
	Total		153	2	155

415 Strong negative Samples were collected from prior to the outbreak of COVID-19 from different
 416 origins, negative samples were collected from during the outbreak of COVID from different
 417 cities of China. SARS-CoV-2 Ab Negative represented no SARS-CoV-2 antibodies were
 418 detected in the sample, SARS-CoV2 Ab Positive represented SARS-CoV-2 antibodies were
 419 detected in the sample.

420 **Table 2 Sensitivity assay against positive samples**

Sources	SARS-CoV-2 Ab	SARS-CoV-2 Ab	Sub	Specificity
	Negative	Positive	Total	
Hospital #1	1	44	45	97.8%
Hospital #2	1	23	24	95.8%
Total		2	67	97.1%

421 Positive samples were collected from COVID-19 infected or recovered patients. Two different
 422 hospitals completed the test independently. SARS-CoV-2 Ab Negative represented no SARS-CoV-2

423 antibodies were detected in the sample, SARS-CoV2 Ab Positive represented SARS-CoV-2
424 antibodies were detected in the sample.

425

426 **Figure 1. Construction and expression of the SARS-CoV-2 S1 protein.**

427 A) Domain structures of SARS-CoV-2 Spike 1 proteins, including full length spike protein S, S1
428 protein with 6*HIS and Fc TAG: the signal peptide was colored with blue or red, S1 domain was
429 coloured with yellow, S2 domain was coloured with green, His tag was coloured with light-blue and
430 Fc tag was coloured with grey.

431 B) SDS-PAGE of S1-His expression and purification: Lane M referred to the MW markers (kDa),
432 lane 1 referred to the culture supernatant, lane 2 referred to the flow-through, lane 3 referred to the
433 1st wash with buffer 1, lane 4 referred to the 2nd wash with buffer 2, lanes 5~8 referred to three
434 different fractions eluted with buffers containing 50 mM MES, 250 mM Imidazole, 150 mM NaCl
435 pH 7.4.

436 C) SDS-PAGE of S1-Fc expression and purification: Lane M referred to the MW markers (kDa),
437 lane 1 referred to the culture supernatant, lanes 2 referred to eluted fractions, lane 3 referred to the
438 flow-through.

439 **Figure 2. Identification of recombinant S1 protein.**

440 A) Recombinant S1-HIS protein was coated on the plate and characterized by plasma samples. The
441 negative samples represented plasmas from non-infected populations and SARS-CoV-2
442 seroconverters indicated plasmas from recovered COVID-19 patients.

443 B) Monkey sera after immunization with S1-Fc. Each well was coated with 100 μ l of S1-
444 His6X at 1 μ g/mL, probed with different concentrations of monkey sera prepared in 20% CS-PBS.
445 After washes, the immune complexes were detected with Goat anti-Human IgG (H + L) peroxidase
446 conjugate (1: 20,000 in 20% CS-PBS). TMB substrate solution was added and OD measured at 450
447 nm wave length in a microplate spectrophotometer.

448 **Figure 3. Kit optimization for the serological assay.**




449 A) Different washing buffers including PBS and PBST were tested. PBS (0.01M phosphate-salt
450 buffer, pH 7.4), PBST-1 (PBS-0.05% tween-20), and PBST-2 (PBS- 0.1% tween-20).

451 B) ~C) Optimization of sample dilution buffer and enzyme dilution buffer.
452 Different buffers were chosen for optimization of sample and enzyme dilution buffers by
453 negative samples (B) and positive controls (C). 20%CS referred to 20% (v/v) calf serum in
454 0.01M phosphate-salt buffer (pH 7.4), 3% BSA referred to 3% (3g/100ml) BSA in 0.01M
455 phosphate-salt buffer (pH 7.4), shake referred to 96-well plate with constant shaking at 200rpm,
456 and manual mean 96-well plate with manual tapings every 10 minutes.


457 **Figure 4. Sensitivity assay of the Kit.**

458 A) ~C) 45 Plasma samples collected from either hospitalized or recovered COVID-19
459 patients were tested with the serological ELISA kit. A) days after onset of diseases, B)
460 different genders, C) different age groups.


461 D) 24 Plasma samples collected from either hospitalized or recovered COVID-19
462 patients, were tested with the serological ELISA kit. The samples were marked by
463 collecting time: Hosp-Day 1 were samples collected one day after hospitalization,
464 Hospitalized were samples collected anytime during the hospitalization, Follow-14
465 follow-up were samples collected on day 14 post-release from the hospital.

A**B****C**


A




B




A




B




C




A



B



C



D

